Preoperative endocrine therapy and the NeoTAILOR trial | Oral Presentation | Wednesday, December 11 | 12:30 PM CT | Prof. Nusayba Bagegni, St. Louis, Missouri |
OPTIMA – Trials updates | Oral Presentation | Wednesday, December 11 | 1:00 PM CT | Kelly Marcom, Medical Director, Veracyte |
Prosigna’s impact on risk stratification in HR+/HER2- EBC: a real-world comparison with OncotypeDX | Oral Presentation | Wednesday, December 11 | 3:00 PM CT | Dr. Nicola Fusco and Dr. Giulia Cursano, IEO, Milan |
How is Prosigna utilised in the United Kingdom? Findings from a multi-centre RWE study | Oral Presentation | Wednesday, December 11 | 5:30 PM CT | Dr. Thiraviyam Elumalai, Cambridge University |
Intrinsic subtype at progression to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2- metastatic breast cancer | Oral Presentation | Thursday, December 12 | 12:30 PM CT | Dr. Francesco Schettini, Hospital Clinic, Barcelona |
Experience with Prosigna assay from a tertiary hospital in Spain | Oral Presentation | Thursday, December 12 | 1:00 PM CT | Dr. Rodrigo Sánchez Bayona, Hospital 12 de octubre, Madrid |
Performance of Genomic Assays in Diverse Populations | Oral Presentation | Thursday, December 12 | 1:30 PM CT | Prof. Melissa Troester, Carolina Breast Cancer Study, University North Carolina |
Unlocking the potential of Prosigna-based trial designs in personalized breast cancer therapeutics | Oral Presentation | Thursday, December 12 | 3:00 PM CT | Dr. Tomás Pascual, Hospital Clinic, Barcelona |
Retrospective Analysis of different gene expression tests in HR+/HER2- breast cancer: correlation of Prosigna with EndoPredict and MammaPrint | Oral Presentation | Thursday, December 12 | 5:30 PM CT | Brigitte Schober, Feldkirch, Austria |
Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in HormonReceptor-Positive/HER2-Negative Metastatic Breast Cancer (MBC) | Abstract Number: SESS-1016 | Thursday, December 12 | – | Francesco Schettini (Spain) |
Comparison of different gene expression tests in breast cancer: poor correlation of Prosigna, EndoPredict and MammaPrint | Abstract Number: SESS-1674 | Thursday, December 12 | – | Brigitte Schober |
Enhancing Risk Stratification in HR + Early Breast Cancer: A Real-World Evaluation of Oncotype Dx and Prosigna | Abstract Number: SESS-1851 | Thursday, December 12 | – | Nicola Fusco (Italy) |
Evaluating the Impact of Prosigna Testing on Adjuvant Chemotherapy Decisions in Early-Stage ER-Positive, HER2-Negative Breast Cancer: A UK Study Thiraviyam Elumalai | Abstract Number: P1-10-12 | Thursday, December 12 | – | Thiraviyam Elumalai (UK) |